Browsing Tag
Leerink Partners
7 posts
Kardigan’s IPO demand looks strong, but the real test for KARD arrives in 2027
Kardigan raises $400 million in an upsized Nasdaq IPO to fund three cardiovascular trials. Discover the catalysts, cash runway and risks for KARD investors.
Did Tango Therapeutics Inc. just turn one cancer data shock into a $600m runway?
Find out how Tango Therapeutics Inc.'s $600 million offering could reshape TNGX sentiment, dilution risk, and its oncology runway.
Is Parabilis Medicines’ $670m Nasdaq IPO a biotech comeback signal or a high-risk oncology wager?
Find out how Parabilis Medicines’ upsized Nasdaq IPO reshapes biotech financing, Regeneron validation and investor appetite for Helicon platform drugs now.
Seaport Therapeutics seeks $212m IPO as neuropsychiatry biotech window reopens
Seaport’s IPO tests biotech appetite before key depression data. Here’s why SPTX, PureTech, and psychiatry investors are watching.
Ligand Pharmaceuticals (LGND) to acquire XOMA Royalty (XOMA) for $739m as biotech royalty consolidation accelerates
Ligand is buying XOMA for $739 million in cash. The real story sits inside a CVR tied to a $19.7 billion Johnson and Johnson royalty fight.
Biotech stocks in trouble? Immatics shares plunge after $150m funding news shocks investors
Immatics N.V. (NASDAQ: IMTX), a clinical-stage biopharmaceutical company focused on cancer immunotherapies, has seen its shares decline significantly…
Centessa Pharmaceuticals pulls off massive $225m deal—Stock price jumps
Centessa Pharmaceuticals has experienced a substantial rise in its share price after completing an upsized public offering of…